Pfizer has reached a settlement with the SEC to receive $29 million from a $602 million fund previously allocated to victims of an insider trading scheme involving a unit of Steven Cohen’s hedge fund. Pfizer claimed its entitlement to the remaining funds, asserting its own victim status in the scandal. The agreement marks an end to Pfizer’s dispute over the distribution of the settlement.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Pfizer, SEC Reach $29M End to Scrap Over Insider Trading Settlement
Pfizer has reached a settlement with the SEC to receive $29 million from a $602 million fund previously allocated to victims of an insider trading scheme involving a unit of Steven Cohen’s hedge fund. Pfizer claimed its entitlement to the remaining funds, asserting its own victim status in the scandal. The agreement marks an end to Pfizer’s dispute over the distribution of the settlement.